Differential diagnosis of obstetric thrombotic microangiopathy: a review

Abstract

Thrombotic microangiopathy (TMA) is a clinical and morphological syndrome, which is based on damage of the endothelium. Clinically, TMA is characterized by a triad of symptoms: thrombocytopenia, microangiopathic hemolytic anemia, and target organ damage. In obstetric practice, TMA most often occurs with preeclampsia or HELLP syndrome, atypical HUS, TTP. The review presents the basic differential criteria for the diagnosis of TMA during pregnancy and after childbirth, as well as the management of patients.

Keywords

preeclampsia / HELLP syndrome / thrombotic thrombocytopenic purpura / hemolytic-uremic syndrome, typical and atypical

References

[1] Kentouche K, Voigt A, Schleussner E, et al. Pregnancy in Upshaw-Schulman syndrome. Hamostaseologie. 2013;33(2):144–148. DOI: 10.5482/HAMO-13-04-0025

[2] Kentouche K., Voigt A., Schleussner E., et al. Pregnancy in Upshaw–Schulman syndrome // Hamostaseologie. 2013. Vol. 33, N 2. P. 144–148. DOI: 10.5482/HAMO-13-04-0025

[3] Akin’shina SV, Bitsadze VO, Andreeva MD, Makatsariya AD. Thrombotic microangiopathy. Prakticheskaya meditsina. 2013;7(76):7–19. (In Russ).

[4] Акиньшина С.В., Бицадзе В.О., Андреева М.Д., Макацария А.Д. Тромботическая микроангиопатия // Практическая медицина. 2013. Т. 7, № 76. С. 7–19.

[5] Dashe JS, Ramin SM, Cunningham FG. The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol. 1998;91(5 Pt1):662–668.

[6] Dashe J.S., Ramin S.M., Cunningham F.G. The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy // Obstet Gynecol. 1998. Vol. 91, N 5 (Pt 1). P. 662–668.

[7] Grebennik TK, Ryabinkina IN, Pavlovich SV, et al. Statistics of pre-eclampsia and eclampsia. Materialy VIII Regional’nogo nauchnogo foruma «Mat’ i ditya»; 2015 June 29 – July 1; Sochi:163–164. (In Russ).

[8] Гребенник Т.К., Рябинкина И.Н., Павлович С.В., и др. Статистика преэклампсии и эклампсии // Материалы VIII Регионального научного форума «Мать и дитя»; 29 июня – 1 июля 2015; Сочи. С. 163–164.

[9] Sarno L, Stefanovic V, Maruotti GM, et al. Thrombotic microangiopathies during pregnancy: The obstetrical and neonatal perspective. Eur J Obstet Gynecol Reprod Biol. 2019;237:7–12. DOI: 10.1016/j.ejogrb.2019.03.018

[10] Sarno L., Stefanovic V., Maruotti G.M., Zullo F., Martinelli P. Thrombotic microangiopathies during pregnancy: The obstetrical and neonatal perspective // Eur J Obstet Gynecol Reprod Biol. 2019. Vol. 237. P. 7–12. DOI: 10.1016/j.ejogrb.2019.03.018

[11] Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am. 2014;32(3):649–671. DOI: 10.1016/j.emc.2014.04.008

[12] Kappler S., Ronan-Bentle S., Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP) // Emerg Med Clin North Am. 2014. Vol. 32, N 3. P. 649–671.

[13] Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost. 2016;42(7):774–779. DOI: 10.1055/s-0036-1587683

[14] Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy // Semin Thromb Hemost. 2016. Vol. 42, N 7. P. 774–779.

[15] Fujisawa M, Yasumoto A, Kato H, et al. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. Br J Haemаtol. 2020;189(1):182–186. DOI: 10.1111/bjh.16297

[16] Fujisawa M., Yasumoto A., Kato H., et al. The role of anti–complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function // Br J Haemotol. 2020. Vol. 189, N 1. P. 182–186.

[17] Roose E, Joly BS. Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura. Hamostaseologie. 2020;40(03):322–336. DOI: 10.1055/a-1171-0473

[18] Roose E., Joly B.S. Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura // Hamostaseologie. 2020. Vol. 40, N 03. P. 322–336. DOI: 10.1055/a-1171-0473

[19] Makatsariya AD, Bitsadze VO, Khizroeva DKh. HELLP syndrome. Akusherstvo. Ginekologiya. Reproduktsiya. 2014;8(2):61–68. (In Russ).

[20] Макацария А.Д., Бицадзе В.О., Хизроева Д.Х. HELLP-синдром // Акушерство. Гинекология. Репродукция. 2014. Т. 8, № 2. С. 61–68.

[21] Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–2735. DOI: 10.1182/blood.v98.9.2730

[22] Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor // Blood. 2001. Vol. 98. P. 2730–2735.

[23] Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine (Baltimore). 1981;60(6):413–428.

[24] Ridolfi R.L., Bell W.R. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature // Medicine (Baltimore). 1981. Vol. 60, N 6. P. 413–428.

[25] Makatsariya AD, Bitsadze VO, Akin’shina SV, Andreeva MD. Pathogenesis and prevention of pregnancy complications caused by thrombotic microangiopathy. Voprosy ginekologii, akusherstva i perinatologii. 2013;12(6):63–73. (In Russ).

[26] Макацария А.Д., Бицадзе В.О., Акиньшина С.В., Андреева М.Д. Патогенез и профилактика осложнений беременности, обусловленных тромботической микроангиопатией // Вопросы гинекологии, акушерства и перинатологии. 2013. Т. 12, № 6. С. 63–73.

[27] Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci. 2016;54:199–202.

[28] Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology // Transfus Apher Sci. 2016. Vol. 54. P. 199–202.

[29] Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859–867.

[30] Fakhouri F., Roumenina L., Provot F., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations // J Am Soc Nephrol. 2010. Vol. 21, N 5. P. 859–867.

[31] Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2017;450–459. DOI: 10.1016/j.kint.2017.06.022

[32] Huerta A., Arjona E., Portoles J., et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome // Kidney Int. 2017. Vol. 93, N 2. P. 450–459. DOI: 10.1016/j.kint.2017.06.022

[33] Gaggl M, Aigner C, Csuka D, et al. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29(3):1020–1029. DOI: 10.1681/ASN.2016090995

[34] Gaggl M., Aigner C., Csuka D., et al. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome // J Am Soc Nephrol. 2018. Vol. 29, N 3. P. 1020–1029. DOI: 10.1681/ASN.2016090995

[35] Haram K, Mortensen JH, Mastrolia SA, Erez O. Disseminated intravascular coagulation in the HELLP syndrome: how much do we really know? J Maternal Fetal Neonatal Med. 2017;30:779–788. DOI: 10.1080/14767058.2016.1189897

[36] Haram K., Mortensen J.H., Mastrolia S.A., Erez O. Disseminated intravascular coagulation in the HELLP syndrome: how much do we really know? // J Maternal Fetal Neonatal Med. 2017. Vol. 30. P. 779–788.

[37] Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.

[38] Moake J.L. Thrombotic microangiopathies // N Engl J Med. 2002. Vol. 347. P. 589–600.

[39] Wu N, Liu J, Yang S, et al. Diagnostic and prognostic values of ADAMTS-13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion. 2015;15(1):18–24. DOI: 10.1111/trf.12762

[40] Wu N., Liu J., Yang S., et al. Diagnostic and prognostic values of ADAMTS-13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura // Transfusion. 2015. Vol. 15, N 1. P. 18–24. DOI: 10.1111/trf.12762

[41] Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–657. DOI: 10.1038/nrneph.2012.214

[42] Zuber J., Fakhouri F., Roumenina L.T., Loirat C., Frémeaux-Bacchi V.; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies // Nat Rev Nephrol. 2012. Vol. 8. P. 643–657.

[43] Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol. 2007;109:956–966.

[44] Sibai B.M. Imitators of severe preeclampsia // Obstet Gynecol. 2007. Vol. 109. P. 956–966.

[45] Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27(7):2673–2685. DOI: 10.1093/ndt/gfs279

[46] Barbour T., Johnson S., Cohney S., Hughes P. Thrombotic microangiopathy and associated renal disorders // Nephrol Dial Transplant. 2012. Vol. 27, N 7. P. 2673–2685.

[47] Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic–uremic syndrome. N Engl J Med. 1995;333(6):364–368.

[48] Boyce T.G., Swerdlow D.L., Griffin P.M. Escherichia coli O157:H7 and the hemolytic–uremic syndrome // N Engl J Med. 1995. Vol. 333, N 6. P. 364–368.

[49] Fujimura Y, Matsumoto M, Kokame K, et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009;144(5):742–754.

[50] Fujimura Y., Matsumoto M., Kokame K., et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients // Br J Haematol. 2009. Vol. 144, N 5. P. 742–754.

[51] Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888–5897. DOI: 10.1182/blood-2012-02-408914

[52] Moatti-Cohen M., Garrec C., Wolf M., et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura // Blood. 2012. Vol. 119, N 24. P. 5888–5897.

[53] Hofer J, Giner T, Safouh H. Diagnosis and treatment of the hemolytic uremic syndrome disease spectrum in developing regions. Semin Thromb Hemost. 2014;40:478–486. DOI: 10.1055/s-0034-1376154

[54] Hofer J., Giner T., Safouh H. Diagnosis and treatment of the hemolytic uremic syndrome disease spectrum in developing regions // Semin Thromb Hemost. 2014. Vol. 40. P. 478–486.

[55] Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res. 2015;165:306–320. DOI: 10.1016/j.trsl.2014.10.010

[56] Wong E.K., Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome // Transl Res. 2015. Vol. 165. P. 306–320.

[57] Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol. 2013;166:117–123. DOI: 10.1016/j.ejogrb.2012.09.026

[58] Abildgaard U., Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review // Eur J Obstet Gynecol Reprod Biol. 2013. Vol. 166. P. 117–123.

[59] Mao M, Chen C. Corticosteroid therapy for management of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome: a meta-analysis. Med Sci Monit. 2015;21:3777–3783.

[60] Mao M., Chen C. Corticosteroid therapy for management of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome: a meta-analysis // Med Sci Monit. 2015. Vol. 21. P. 3777–3783.

[61] LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819–826. DOI: 10.7326/M14-1884.

[62] LeFevre M.L.; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement // Ann Intern Med. 2014. Vol. 161, N 11. P. 819–826.

RIGHTS & PERMISSIONS

Eco-Vector